Guggenheim Initiates Coverage On Myriad Genetics with Buy Rating, Announces Price Target of $23
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Subbu Nambi has initiated coverage on Myriad Genetics (NASDAQ:MYGN) with a Buy rating and set a price target of $23.
December 14, 2023 | 11:36 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guggenheim analyst Subbu Nambi initiated coverage on Myriad Genetics with a Buy rating and a price target of $23.
Analyst ratings, especially initiations of coverage with a Buy rating, can have a positive impact on a stock's price in the short term. The price target of $23 suggests a significant upside potential from the current trading price, assuming the market aligns with the analyst's valuation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100